Helios Cardio
MA - WestonBiotechnology
Focus: Helios Cardio is a publicly traded biotechnology company developing regenerative biologic matrices, with a focus on cardiac tissue repair. The company operates at an early-stage development phase with a lean pipeline concentrated in atrial fibrillation indications.
Profile data last refreshed 14h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
2
Should You Work at Helios Cardio?
AI assessmentHelios Cardio offers deep scientific work in regenerative cardiology but with constrained near-term growth and visibility risk due to early pipeline maturity and minimal active hiring.
Why Work Here
- Opportunity to work on innovative regenerative medicine technology (CardiaMend biologic matrices) in a high-unmet-need cardiovascular space
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
CardiaMend in Combination with Amiodarone
Atrial FibrillationClinical Trials (1)
NCT06063538Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone
Phase 1Help build intelligence for Helios Cardio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.